China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q1 2025 earnings summary

Executive summary

• Q1 2025 revenue was RMB 6.85 billion, down 6.04% year-over-year; net profit attributable to shareholders was RMB 1.27 billion, down 6.87% year-over-year.

• The company completed the acquisition of a 28% stake in Tasly, making it a controlling subsidiary and enhancing industry chain synergy.

• Faced with a challenging market, the company focused on optimizing business structure, integrating resources, and accelerating innovation.

Financial highlights

• Operating cash flow increased 24.57% year-over-year to RMB 979.86 million.

• Total assets at quarter-end were RMB 57.85 billion, up 44.32% from year-end 2024; shareholders' equity rose 6.41% to RMB 21.18 billion.

• Basic EPS was RMB 1.00, down 6.54% year-over-year; weighted average ROE was 6.18%, down 0.76 percentage points.

• Non-recurring profit and loss items contributed RMB 51.82 million, mainly from government subsidies and asset disposals.

Outlook and guidance

• The company aims to leverage the Tasly acquisition for R&D, manufacturing, and marketing synergies, strengthening its position in innovative Chinese medicine.

• Focus remains on high-quality growth, business structure optimization, and expanding core product pipelines.